Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 Apr 18;23(16):4550–4555. doi: 10.1158/1078-0432.CCR-17-0234

Table 3.

Summary of antitumor responses

Best response T-Cell NHL
n, (%)a
B-Cell NHL
n, (%)
leukemia / myeloma/other
n, (%)a
CR/CRu 2 (17%) 0 0
PRu 2 (17%) 1 (9%) 0
SD 5 (42%) 2 (18%) 0
PD 2 (18%) 8 (73%) 4 (100%)
Inevaluableb 2 0 1
a

Of evaluable patients

b

T-Cell: one patient withdrew after Course 1, one patient lost to follow-up; one ALL leukemia patient proceeded to marrow transplant after three courses.